Pediatric Leishmaniasis Workup
- Author: Conjivaram Vidyashankar, MD, MRCP; Chief Editor: Russell W Steele, MD more...
Laboratory Studies
The parasite can be detected through direct evidence from peripheral blood, bone marrow, or splenic aspirates, as explained below. The smears are stained in Leishman, Giemsa, or Wright stains and examined under oil immersion microscope.
Peripheral blood smear
Amastigotes are revealed inside the circulating monocytes and neutrophils. However, they are often difficult to locate because of the small numbers. L donovani is best detected using the following methods: (1) creating thick film by producing a single straight leukocyte edge when making a peripheral smear or (2) centrifuging citrated blood and withdrawing the sediment, which is then smeared, dried, and stained.
Culture
Obtaining a culture is time consuming, and findings take approximately a month. Cultures are made using a Novy-McNeal-Nicolle medium. The medium is a rabbit-blood agar that has an overlay of Locke solution with added antibiotics. Two mL of blood is aseptically obtained from a vein and is diluted with 10 mL of citrated saline solution. This is centrifuged and the cellular deposit is inoculated into the water of condensation of nitrosonornicotine (NNN) medium and incubated at 22°C for 1-4 weeks. At the end of each week, a drop of condensation fluid is examined for promastigote forms.
Polymerase chain reaction
Parasite DNA can be identified using polymerase chain reaction (PCR).[1]
Animal inoculation
This is a sensitive method but can take several weeks. The sample is inoculated intraperitoneally or intradermally into skin on the nose and feet. The parasites can be demonstrated from the ulcers and nodules that develop from the sites of inoculation.
Indirect Evidence of Infection
Detection of hypergammaglobinemia
The aldehyde test and the antimony test were the initial tests used to diagnose kala azar.
Aldehyde test results reveal increased gamma globulin levels. Obtain approximately 1 mL of blood in a small glass tube and add 1-2 drops of 40% formalin. The formation of milky whitelike opacity and jellification indicates a positive result. Aldehyde test findings are not positive unless the disease has been present for at least 3 months.
Antimony test findings also depend on a rise in serum gamma globulin levels. Positive findings are indicated by a white flocculent precipitate observed when a urea stibamine solution comes in contact with serum.
Immunological tests
Before the use of specific leishmanial antigens, nonspecific antigens were used. These include the Witebsky, Klingenstein, Kuhn (WKK) antigen from the tubercle bacilli and an antigen from the Kedrowsky acid-fast bacillus. False-positive results occur in patients with tuberculosis, leprosy, and tropical Eosinophilia infection. The direct agglutination test, which detects the specific immunoglobulin M (IgM) antibody at an early stage, has been found to be useful in the detection of both clinical and subclinical infections. Because this test is easy to perform and the results are available in 24 hours, it can be used as a rapid test in primary care settings. Antibodies to the K39 antigen have been found to have high sensitivity and specificity in rapid diagnosis of visceral leishmaniasis, including a recent K39 immunochromatographic test and a K39 strip test.[2]
Nonspecific tests
Specific leishmanial antigens prepared from cultures have been used in a number of tests. The direct agglutination test, immunofluorescent antibody test, complement fixation, and counterimmunoelectrophoresis are the various tests used in diagnosis of kala azar. Cross-reactions can occur with leprosy, Chagas disease, malaria, and schistosomiasis. Polymerase chain reaction (PCR) has also been used in the diagnosis of leishmaniasis using sequences from the variable region of kinetoplast DNA. A negative serological test result does not exclude the possibility of a leishmanial infection.
An immunochromatographic test for detection of anti–rK-39 antibodies has been reported with high sensitivity and specificity in diagnosis of visceral leishmaniasis and post–kala azar dermal leishmaniasis.
Leishmanin skin test (Montenegro test) is a delayed hypersensitivity reaction introduced in Montenegro, South America. It is performed by intradermally injecting 0.1 mL of killed promastigote antigen. The test results are available after 72 hours. The leishmanin skin test results are negative during active visceral leishmaniasis and usually become positive only after successful therapy. The test results are also positive in patients with dermal leishmaniasis. This test is useful only for epidemiological purposes, indicating prior exposure to infection.
Supportive tests
Hematological parameters include the following: blood examination findings reveal a normochromic normocytic anemia, leukopenia, neutropenia, thrombocytopenia, elevated gamma globulin levels, and a reversal of the albumin-globulin ratio.
Procedures
Bone marrow aspiration is the most common sample obtained. Samples are obtained from the sternum or the iliac crest. Amastigote forms are revealed in plain film, and the promastigote forms are revealed in culture. Although safer than splenic puncture, the parasites are scant and may give a false-negative test result. Positivity rates ranging from 54-86% have been obtained using bone marrow.
When the spleen is enlarged considerably, splenic aspiration is one of the valuable methods for obtaining a positive result. As many as 98% of positive results have been obtained using splenic aspiration. Amastigote forms are revealed in stained specimens, and the promastigote forms are revealed in culture. Splenic puncture is associated with the risk of uncontrolled hemorrhage and, therefore, should be carried out only when bone marrow examination findings are inconclusive. Platelet counts and prothrombin times should be checked before the procedure.
Lymph node aspiration or biopsy may be helpful in the presence of enlarged lymph nodes. In cutaneous disease, tissue can be obtained with a 3-mm punch biopsy, lesion scrapings, or needle aspiration of the nonnecrotic edge of the lesion.
Histologic Findings
Leishmaniasis is a disease that involves the reticuloendothelial system. The parasitized macrophages disseminate infection to all parts of the body, especially to the spleen, liver, and bone marrow.
The spleen is enlarged, with a thickening of the capsule, it is soft and fragile, its vascular spaces are dilated and engorged with blood, and the reticular cells of Billroth are markedly increased and packed with amastigote forms of the parasite. However, no evidence of fibrosis is present.
In the liver, the Kupffer cells are increased in size and number and infected with amastigote forms of Leishmania. The bone marrow is hyperplastic, and parasitized macrophages replace the normal hemopoietic tissue.
Alam MZ, Shamsuzzaman AK, Kuhls K, Schonian G. PCR diagnosis of visceral leishmaniasis in an endemic region, Mymensingh district, Bangladesh. Trop Med Int Health. May 2009;14(5):499-503. [Medline].
Monno R, Giannelli G, Rizzo C, De Vito D, Fumarola L. Recombinant K39 immunochromatographic test for diagnosis of human leishmaniasis. Future Microbiol. Mar 2009;4(2):159-70. [Medline].
Avasthi R, Chaudhary SC, Khanna S. Visceral leishmaniasis simulating chronic liver disease: successful treatment with miltefosine. Indian J Med Microbiol. Jan-Mar 2009;27(1):85-6. [Medline].
Rahman M, Ahmed BN, Faiz MA, Chowdhury MZ, Islam QT, Sayeedur R, et al. Phase IV Trial of Miltefosine in Adults and Children for Treatment of Visceral Leishmaniasis (Kala-Azar) in Bangladesh. Am J Trop Med Hyg. Jul 2011;85(1):66-69. [Medline].
[Guideline] Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. Apr 10 2009;58:1-207; quiz CE1-4. [Medline].
Tiuman TS, Santos AO, Ueda-Nakamura T, Filho BP, Nakamura CV. Recent advances in leishmaniasis treatment. Int J Infect Dis. May 22 2011;[Medline].
Braunwald E, Fauci AS, Hauser SL, et al. Leishmaniasis. In: Harrison's Manual of Medicine. 15th ed. McGraw-Hill; 2001.
Masmoudi A, Dammak A, Chaaben H, Maalej N, Akrout F, Turki H. Doxycycline for the treatment of cutaneous leishmaniasis. Dermatol Online J. Aug 15 2008;14(8):22. [Medline].
Machado PR, Ampuero J, Guimaraes LH, et al. Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial. PLoS Negl Trop Dis. 2010;4(12):e912. [Medline].
Berman J. Clinical status of agents being developed for leishmaniasis. Expert Opin Investig Drugs. 2005;1337-1346. [Medline].
Bimal S, Das VN, Sinha PK, et al. Usefulness of the direct agglutination test in the early detection of subclinical Leishmania donovani infection: a community-based study. Annals of Tropical Medicine and Parasitology. 2005;99:743-749. [Medline].
Blair JS. Sir William Leishman. J R Army Med Corps. Sep 2008;154(3):212-3. [Medline].
Bucheton B, Abel L, El-Safi S, et al. A major susceptibility locus on chromosome 22q12 plays a critical role in the control of kala-azar. Am J Hum Genet. Nov 2003;73(5):1052-60. [Medline].
Catania S, Aiassa C, Tzahtzoglou S, et al. Visceral leishmaniasis treated with liposomal amphotericin B. Pediatr Infect Dis J. Jan 1999;18(1):73-4. [Medline].
Chatterjee KD. Parasitology and Helminthology. 11th ed. Calcutta: Chatterjee Medical Publishers; 1976:54-69.
Das VN, Ranjan A, Bimal S, et al. Magnitude of unresponsiveness to sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar. Natl Med J India. May-Jun 2005;18(3):131-3. [Medline].
Goswami RP, Bairagi B, Kundu PK. K39 strip test--easy, reliable and cost-effective field diagnosis for visceral leishmaniasis in India. J Assoc Physicians India. Aug 2003;51:759-61. [Medline].
Handman E, Elso C, Foote S. Genes and susceptibility to leishmaniasis. Adv Parasitol. 2005;59:1-75. [Medline].
Jha TK, Olliaro P, Thakur CP, et al. Randomized controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India. BMJ. Apr 18 1998;316(7139):1200-5. [Medline].
Lindoso JA, Barbosa RN, Posada-Vergara MP, et al. Unusual manifestations of tegumentary leishmaniasis in AIDS patients from the New World. Br J Dermatol. Feb 2009;160(2):311-8. [Medline].
Mahajan V, Marwaha RK. Immune Mediated Hemolysis in Visceral Leishmaniasis. J Trop Pediatr. May 4 2007;[Medline].
Miller EN, Fadl M, Mohamed HS, et al. Y chromosome lineage- and village-specific genes on chromosomes 1p22 and 6q27 control visceral leishmaniasis in Sudan. PLoS Genet. May 11 2007;3(5):e71. [Medline].
Mishra J, Saxena A, Singh S. Chemotherapy of leishmaniasis: past, present and future. Curr Med Chem. 2007;14(10):1153-69. [Medline].
Murray HW, Berman JD, Davies CR, Saravia NG. Advances in leishmaniasis. Lancet. Oct 29-Nov 4 2005;366(9496):1561-77. [Medline].
Olliaro PL, Guerin PJ, Gerstl S, et al. Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004. Lancet Infectious Diseases. 2005;763-774. [Medline].
Pahwa R, Gupta SK, Singh T, Nigam S. Acute fulminant visceral leishmaniasis in children--a report of two cases. Indian Journal of Pathology and Microbiology. 2004;47:428-430. [Medline].
Pearson RD, De Queiroz Sousa A. Leishmania species: visceral, cutaneous and mucosal leishmaniasis. In: Mendell, Bennet, Douglas, eds. Principles and Practice of Infectious Diseases. 3rd ed. London: Churchill Livingstone; 1990:2066-77.
Pearson RD, Lareau SM, Jeronimo SM. Leishmaniasis at the End of the Millennium. Curr Infect Dis Rep. Dec 1999;1(5):448-452. [Medline].
Prasad LS. Kala azar. Indian J Pediatr. Jul-Aug 1999;66(4):539-46. [Medline].
Rajapaksa US, Ihalamulla RL, Udagedera C, Karunaweera ND. Cutaneous leishmaniasis in southern Sri Lanka. Trans R Soc Trop Med Hyg. Aug 2007;101(8):799-803. [Medline].
Schaefer KU, Schoone GJ, Gachihi GS, et al. Visceral leishmaniasis: use of the polymerase chain reaction in an epidemiological study in Baringo District, Kenya. Trans R Soc Trop Med Hyg. Sep-Oct 1995;89(5):492-5. [Medline].
Singh UK, Sinha RK, Sharma VK. Fulminant hepatitis in Kala-azar. Indian J Pediatr. Sep-Oct 1995;62(5):571-4. [Medline].
Sinha PK, Ranjan A, Singh VP, et al. Visceral leishmaniasis (kala-azar)-the Bihar (India) perspective. J Infect. Oct 31 2005;[Medline].
Sundar S, Goyal AK, Mandal AK, et al. Amphotericin B lipid complex in the management of antimony unresponsive Indian visceral leishmaniasis. J Assoc Physicians India. Feb 1999;47(2):186-8. [Medline].
Sundar S, Rai M. Treatment of visceral leishmaniasis. Expert Opinion in Pharmacotherapy. 2005;2821-2829. [Medline].
Thakur CP. A comparison of intercostal and abdominal routes of splenic aspiration and bone marrow aspiration in the diagnosis of visceral leishmaniasis. Trans R Soc Trop Med Hyg. Nov-Dec 1997;91(6):668-70. [Medline].
Webster TL Jr. Drugs used in the chemotherapy of protozoal infections. In: Goodman & Gilman's: The Pharmacological Basis of Therapeutics. 8th ed. McGraw-Hill; 1995:1008-17.

